Multicentric Randomized Phase I/IIa Trial of the Safety and Immunogenicity of a Therapeutic Anti-HPV DC Targeting Vaccine in Patients With Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti-CD40-HPV-vaccine-LinKinVax (Primary) ; Poly ICLC
Indications Carcinoma; Human papillomavirus infections; Oropharyngeal cancer
Focus Adverse reactions; First in man; Therapeutic Use

09 Dec 2024 According to EnnoDC media release, preliminary data from this trial will be presented at the ESMO Immuno-Oncology Congress 2024, 11-13 December 2024 in Geneva, Switzerland. The upcoming results from this trial expected in the coming months.
18 Sep 2023 According to a LinKinVax media release, the company announced the treatment at Gustave Roussy of the first patient in a Phase I/IIa clinical study with CD40HVac
24 Aug 2023 Status changed from planning to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com